Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transcatheter Aortic Valve Replacement | 12 | 2023 | 57 | 2.020 |
Why?
|
| Aortic Valve Stenosis | 13 | 2023 | 84 | 1.940 |
Why?
|
| Heart Valve Prosthesis | 10 | 2023 | 60 | 1.510 |
Why?
|
| Aortic Valve | 10 | 2023 | 90 | 1.050 |
Why?
|
| Coronary Artery Disease | 4 | 2020 | 216 | 0.570 |
Why?
|
| Drug-Eluting Stents | 4 | 2010 | 102 | 0.550 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2010 | 52 | 0.500 |
Why?
|
| Treatment Outcome | 17 | 2023 | 2285 | 0.470 |
Why?
|
| Hemodynamics | 5 | 2023 | 220 | 0.450 |
Why?
|
| Endovascular Procedures | 2 | 2012 | 61 | 0.450 |
Why?
|
| Heparin Antagonists | 1 | 2011 | 3 | 0.370 |
Why?
|
| Protamines | 1 | 2011 | 11 | 0.370 |
Why?
|
| Femoral Artery | 1 | 2011 | 58 | 0.360 |
Why?
|
| Coronary Thrombosis | 1 | 2010 | 36 | 0.340 |
Why?
|
| Coronary Stenosis | 2 | 2020 | 19 | 0.340 |
Why?
|
| Diabetes Complications | 1 | 2010 | 66 | 0.340 |
Why?
|
| Thrombosis | 2 | 2023 | 147 | 0.340 |
Why?
|
| Sirolimus | 1 | 2010 | 69 | 0.330 |
Why?
|
| Cardiac Catheterization | 3 | 2020 | 112 | 0.330 |
Why?
|
| Aged | 17 | 2021 | 5229 | 0.330 |
Why?
|
| Paclitaxel | 1 | 2010 | 184 | 0.320 |
Why?
|
| Prospective Studies | 10 | 2023 | 1221 | 0.320 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 142 | 0.320 |
Why?
|
| Risk Factors | 13 | 2023 | 2038 | 0.310 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 119 | 0.310 |
Why?
|
| Feasibility Studies | 7 | 2021 | 191 | 0.310 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 447 | 0.290 |
Why?
|
| Prosthesis Design | 6 | 2022 | 85 | 0.270 |
Why?
|
| Risk Assessment | 10 | 2020 | 598 | 0.250 |
Why?
|
| Stroke | 2 | 2023 | 241 | 0.240 |
Why?
|
| Time Factors | 7 | 2021 | 1571 | 0.230 |
Why?
|
| Male | 18 | 2021 | 13041 | 0.230 |
Why?
|
| Myocardial Infarction | 3 | 2011 | 342 | 0.220 |
Why?
|
| Humans | 25 | 2023 | 27165 | 0.220 |
Why?
|
| Female | 18 | 2021 | 14661 | 0.210 |
Why?
|
| Middle Aged | 12 | 2020 | 6912 | 0.200 |
Why?
|
| Coronary Occlusion | 1 | 2022 | 39 | 0.190 |
Why?
|
| Cohort Studies | 4 | 2011 | 864 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 1943 | 0.180 |
Why?
|
| Cell Phone | 2 | 2011 | 19 | 0.180 |
Why?
|
| United States | 8 | 2021 | 2063 | 0.180 |
Why?
|
| Bioprosthesis | 1 | 2020 | 19 | 0.170 |
Why?
|
| Heart Valve Diseases | 1 | 2020 | 26 | 0.170 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 989 | 0.160 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2020 | 48 | 0.160 |
Why?
|
| Coronary Vessels | 1 | 2020 | 151 | 0.160 |
Why?
|
| Retrospective Studies | 8 | 2012 | 2456 | 0.150 |
Why?
|
| Telemedicine | 2 | 2011 | 164 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 466 | 0.150 |
Why?
|
| Comorbidity | 3 | 2020 | 252 | 0.140 |
Why?
|
| Patient Selection | 3 | 2010 | 143 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 472 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2010 | 45 | 0.110 |
Why?
|
| Stents | 2 | 2012 | 116 | 0.100 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 55 | 0.100 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 37 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2019 | 605 | 0.090 |
Why?
|
| Registries | 2 | 2010 | 384 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2012 | 67 | 0.090 |
Why?
|
| Videotape Recording | 1 | 2011 | 8 | 0.090 |
Why?
|
| Video Recording | 1 | 2011 | 38 | 0.090 |
Why?
|
| District of Columbia | 4 | 2012 | 8 | 0.090 |
Why?
|
| Cardiology Service, Hospital | 1 | 2010 | 5 | 0.090 |
Why?
|
| After-Hours Care | 1 | 2010 | 5 | 0.090 |
Why?
|
| Private Sector | 1 | 2010 | 3 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2010 | 30 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 290 | 0.090 |
Why?
|
| Insurance, Health | 1 | 2010 | 51 | 0.090 |
Why?
|
| Patient Transfer | 1 | 2010 | 42 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2010 | 49 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 78 | 0.090 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2010 | 4 | 0.090 |
Why?
|
| Collateral Circulation | 1 | 2010 | 12 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2010 | 78 | 0.090 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2010 | 40 | 0.090 |
Why?
|
| Computed Tomography Angiography | 2 | 2020 | 24 | 0.090 |
Why?
|
| Medicaid | 1 | 2010 | 52 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 26 | 0.080 |
Why?
|
| Iliac Artery | 1 | 2010 | 19 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 73 | 0.080 |
Why?
|
| Medicare | 1 | 2010 | 119 | 0.080 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2010 | 44 | 0.080 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2010 | 63 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2011 | 391 | 0.080 |
Why?
|
| Coronary Angiography | 3 | 2020 | 150 | 0.080 |
Why?
|
| Emergencies | 1 | 2009 | 28 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2011 | 707 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2010 | 84 | 0.080 |
Why?
|
| Coronary Restenosis | 1 | 2009 | 21 | 0.080 |
Why?
|
| Recovery of Function | 2 | 2020 | 112 | 0.080 |
Why?
|
| Reoperation | 1 | 2009 | 144 | 0.080 |
Why?
|
| Coronary Artery Bypass | 1 | 2009 | 68 | 0.080 |
Why?
|
| Aspirin | 2 | 2021 | 122 | 0.060 |
Why?
|
| Tomography | 1 | 2022 | 17 | 0.050 |
Why?
|
| Constriction, Pathologic | 2 | 2012 | 34 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2021 | 34 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2012 | 146 | 0.050 |
Why?
|
| Echocardiography | 1 | 2021 | 108 | 0.040 |
Why?
|
| Multidetector Computed Tomography | 1 | 2020 | 4 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 12 | 0.040 |
Why?
|
| Warfarin | 1 | 2021 | 94 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2020 | 5 | 0.040 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2019 | 4 | 0.040 |
Why?
|
| Echocardiography, Doppler | 1 | 2019 | 21 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2010 | 230 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2019 | 21 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2010 | 278 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 76 | 0.040 |
Why?
|
| Survival Rate | 2 | 2010 | 411 | 0.040 |
Why?
|
| Trauma Severity Indices | 1 | 2019 | 37 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2010 | 190 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 751 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 478 | 0.040 |
Why?
|
| Incidence | 2 | 2010 | 553 | 0.040 |
Why?
|
| Phlebography | 1 | 2012 | 20 | 0.030 |
Why?
|
| Femoral Vein | 1 | 2012 | 13 | 0.030 |
Why?
|
| Equipment Design | 1 | 2012 | 212 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2011 | 11 | 0.020 |
Why?
|
| Hirudins | 1 | 2010 | 17 | 0.020 |
Why?
|
| Antithrombins | 1 | 2010 | 28 | 0.020 |
Why?
|
| Drug Costs | 1 | 2010 | 17 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 144 | 0.020 |
Why?
|
| Workload | 1 | 2010 | 38 | 0.020 |
Why?
|
| Critical Care | 1 | 2010 | 48 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2010 | 14 | 0.020 |
Why?
|
| Inpatients | 1 | 2010 | 56 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 140 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2010 | 73 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2010 | 34 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 2010 | 24 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2010 | 94 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 316 | 0.020 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 64 | 0.020 |
Why?
|
| Length of Stay | 1 | 2010 | 216 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 90 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2010 | 87 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 397 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 408 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2010 | 200 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 88 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 399 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 235 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2010 | 163 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2010 | 293 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 763 | 0.020 |
Why?
|
| Neoplasms | 1 | 2010 | 768 | 0.010 |
Why?
|